By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central Florida, Pensacola, FL 2. Mayo Clinic, Rochester, MN 3. University of Washington/Fred Hutch Cancer Center, Seattle, WA
Bellevue, WA – October 24, 2024 The Binaytara Foundation, a leading global cancer non-profit organization dedicated to improving access to cancer care, is set to host its annual Global Oncology Summit on
More
ESMO 2023 Update – KEYNOTE-671: The First Perioperative Immunotherapy Clinical Trial in Non-Small Cell Lung Cancer Improving Overall Survival Author: Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic, Head & Neck Medical Oncology
More
ESMO 2023 Update – MARIPOSA: Amivantamab + Lazertinib Improves Progression-Free Survival Compared to Osimertinib in EGFR-Mutated, Treatment-Naïve Non-Small Cell Lung Cancer Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic, Head & Neck
More
ESMO 2023 Update – ALINA: Adjuvant Alectinib Improves Disease-Free Survival in Resected Early-Stage Non-Small Cell Lung Cancer Author: Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic, Head & Neck Medical Oncology University of
More
ESMO 2023 Update – CheckMate 77T: Another Phase 3 Trial of Perioperative Immunotherapy Improving Event-Free Survival for Resectable Stage II-III Non-Small Cell Lung Cancer Author: Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic,
More
On October 11, 2023, the U.S. Food and Drug Administration granted approval to Encorafenib (BRAF inhibitor) with Binimetinib (MEK inhibitor) for patients with metastatic non-small cell lung cancer (NSCLC) that was detected
More
Author: Saramshika Dhakal, MBBS Tribhuvan University Teaching Hospital, Kathmandu, Nepal. In a recent article published in JAMA Oncology (JAMA Oncol. 2023;9(4):465-472; researcher Simiao Chen and the team have estimated that the
More
On September 26, the U.S. Food and Drug Administration expanded the approval of bosutinib (Bosulif) to include pediatric patients 1 year of age and older. Previously, bosutinib had been approved for adults
More
Presented by: Chris Chen, MD, Director, Early Drug Development, Stanford Cancer Institute Covered by: Inas Abuali, MD, FACP Dr. Chris Chen, director of the Early Drug Development Program at Stanford Cancer Institute,
More
On August 28, 2023, the U.S. Food and Drug Administration approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) without prior erythropoiesis-stimulating agent (ESA) use,
More